Our Take
4baseCare is chasing a real gap — most cancer genomic datasets come from Caucasian populations — but the company's revenue (₹40 crore annually) and test volume (1,500/month today) suggest it remains a regional operator, not yet a global infrastructure play.
Why it matters
Genomic testing for cancer is moving out of metros and into tier-2 cities across India and emerging markets, but dataset bias in AI-driven diagnosis remains a structural problem in clinical oncology. This round signals venture conviction in population-specific precision medicine as a standalone business, not a footnote to pharma research.
Do this week
Healthcare CIOs: audit whether your cancer centers are capturing genomic data standardly and linking it to treatment outcomes; 4baseCare's decentralized lab model (in-hospital testing vs. centralized shipping) is now operationally viable and may cut turnaround time from weeks to days.
4baseCare closes ₹128 crore funding after two rounds
Precision oncology startup 4baseCare announced the close of ₹128 crore in funding across two tranches. The first was ₹90 crore from investor Ashish Kacholia, Lashit Sanghvi, and existing backer Yali Capital. The second, a ₹38 crore top-up, was led by growX Ventures and Infosys, with participation from existing investors (company-reported). The capital will be deployed to expand genomics laboratory networks globally and scale OncoTwin, the company's AI-driven oncology platform.
4baseCare operates labs in India, Dubai, Nepal, and the Philippines and plans to enter 8-10 additional countries over the next 12-18 months. In India, the company is decentralizing testing infrastructure by partnering with Max Healthcare, AIIMS Jammu, and Shankara Hospital to set up in-hospital genomics labs instead of centralizing all samples in Bengaluru. Currently, 4baseCare conducts around 1,500 genomic tests per month across four active labs in India and expects to scale to 8,000-10,000 tests monthly following expansion (company-reported).
The startup, which reached revenue positive status in 2021 and currently generates approximately ₹40 crore in annual revenue, projects crossing ₹100 crore within the next 12-18 months (company-reported). Founded in 2019 by Hitesh Goswami and Kshitij Rishi, the company develops genomics-driven cancer diagnostics and AI-powered clinical decision support tools.
Cancer genomics in emerging markets remains under-served
Most global genomic datasets used for drug discovery, clinical trials, and treatment insights remain concentrated in the US and Europe, with heavy bias toward Caucasian populations. India alone sees nearly 15 lakh new cancer cases annually, with approximately 70% diagnosed at advanced stages where targeted therapy and immunotherapy become critical. Genomic testing identifies molecular changes in tumors and maps patients to more personalized treatments, yet adoption outside tier-1 hospitals has been slow due to cost and infrastructure constraints.
4baseCare claims to have lowered genomic testing costs to roughly one-fourth of competing offerings (company-reported). The company's stated goal is to integrate genomic testing into public health schemes such as Ayushman Bharat. Adoption is now spreading beyond metro hospitals into tier-2 and tier-3 cities across regions including Jammu and Kashmir and Rajasthan, driven partly by affordability initiatives and industry-sponsored programs (company-reported).
OncoTwin uses multimodal datasets—genomic, pathology, radiology, and clinical information—to create digital twins of cancer patients and match them with similar treatment journeys and outcomes. The platform does not recommend treatment directly but provides physicians with real-world evidence from comparable cases across datasets (company-reported).
What hospital and lab leaders should monitor
Decentralized genomic testing is now operationally viable. In-hospital labs reduce sample shipping delays and turnaround time while enabling local research collaboration and improving diagnostic accessibility. If your hospital network spans multiple cities, audit whether centralized genomic testing is still the default and whether partnerships with providers like 4baseCare, Max Healthcare, or regional labs could cut processing time and cost per test.
Infosys's participation signals enterprise appetite for healthcare AI and data platforms that work across multiple patient populations. If you operate a large health system or pharma company, expect greater integration pressure between genomic testing platforms and clinical decision-support tools built on your own patient cohorts. Legacy labs that do not link test results to treatment outcomes and cost data will face competitive pressure as AI-driven matching becomes standard.